Skip to main content
Premium Trial:

Request an Annual Quote

SGX and Serono to Collaborate on Kinase and Phosphatase Drugs

NEW YORK, March 23 (GenomeWeb News) - Structural Genomix and Serono will collaborate on developing drugs that target kinases and phosphatases, SGX said today.

 

Under the agreement, SGX will use its X-ray crystallography-based approach, called Fragments of Active Structures, to generate lead compounds against kinase and phosphatase targets provided by Serono. Geneva, Switzerland-based Serono will develop and commercialize drug candidates resulting from the collaboration.

 

In return, San Diego-based SGX will receive up to $68 million in upfront and research fees and milestone payments. In addition, it will obtain royalties from sales of drugs.

 

SGX's FAST approach combines screening of lead-like drug fragments using X-ray crystallography with computational design and chemical synthesis.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.